secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-06-12T20:05:16+00:00
Accession:  0001193125-26-269358
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio rebalances board classes, shareholders approve stock plan amendment
-------------------------------------------------------------------------

- Daniel Curran re-elected Class II director, then resigned and reappointed Class III to equalize board classes; no compensation change.
- Stockholders approved Amended and Restated 2021 Stock Incentive Plan, adding prefunded warrant shares to annual evergreen increase.
- All four Class II director nominees and ratification of Ernst & Young as auditor approved at June 10, 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/0001193125-26-269358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/xlo-20260610.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-269358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer